Form 4: X4 Pharmaceuticals CEO Paula Ragan Sells Shares Under 10b5-1 Trading Plan

Paula Ragan, CEO of X4 Pharmaceuticals, sold 31,897 shares of common stock at an average price of $0.562 per share on October 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 15, 2024, Paula Ragan, the President and CEO of X4 Pharmaceuticals, sold 31,897 shares of the company's common stock.
• The sale was executed at a weighted average price of $0.562 per share.
• The transactions occurred within a price range of $0.5424 to $0.5806.
• The sale was conducted under a pre-existing Rule 10b5-1 trading plan adopted on June 28, 2024.
• Following the transaction, Paula Ragan directly owns 1,025,816 shares of X4 Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a routine disclosure of a pre-planned stock sale. The sale itself doesn't necessarily indicate a positive or negative outlook on the company's future.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The market will likely interpret this sale in the context of the company's overall performance and future prospects.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, depending on how the market interprets the transaction.

Key Dates